nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—ABCB1—ovarian cancer	0.331	1	CbGaD
Alitretinoin—ABCB1—Topotecan—ovarian cancer	0.0221	0.354	CbGbCtD
Alitretinoin—ABCB1—Vinorelbine—ovarian cancer	0.0156	0.25	CbGbCtD
Alitretinoin—ABCB1—Paclitaxel—ovarian cancer	0.0109	0.175	CbGbCtD
Alitretinoin—ABCB1—Docetaxel—ovarian cancer	0.00791	0.127	CbGbCtD
Alitretinoin—ABCB1—Doxorubicin—ovarian cancer	0.0059	0.0945	CbGbCtD
Alitretinoin—CRABP1—embryo—ovarian cancer	0.00538	0.0429	CbGeAlD
Alitretinoin—CRABP2—myometrium—ovarian cancer	0.00506	0.0404	CbGeAlD
Alitretinoin—CRABP2—embryo—ovarian cancer	0.00486	0.0388	CbGeAlD
Alitretinoin—CRABP1—uterine cervix—ovarian cancer	0.00435	0.0347	CbGeAlD
Alitretinoin—CRABP2—uterine cervix—ovarian cancer	0.00393	0.0314	CbGeAlD
Alitretinoin—CRABP2—decidua—ovarian cancer	0.00375	0.0299	CbGeAlD
Alitretinoin—CRABP1—gonad—ovarian cancer	0.00365	0.0291	CbGeAlD
Alitretinoin—CRABP2—endometrium—ovarian cancer	0.00356	0.0284	CbGeAlD
Alitretinoin—RARA—myometrium—ovarian cancer	0.00347	0.0277	CbGeAlD
Alitretinoin—CRABP2—gonad—ovarian cancer	0.0033	0.0263	CbGeAlD
Alitretinoin—CRABP1—female reproductive system—ovarian cancer	0.00326	0.026	CbGeAlD
Alitretinoin—RXRB—decidua—ovarian cancer	0.00308	0.0246	CbGeAlD
Alitretinoin—CRABP1—vagina—ovarian cancer	0.00295	0.0235	CbGeAlD
Alitretinoin—CRABP2—female reproductive system—ovarian cancer	0.00295	0.0235	CbGeAlD
Alitretinoin—RXRA—female reproductive system—ovarian cancer	0.00293	0.0234	CbGeAlD
Alitretinoin—RARG—decidua—ovarian cancer	0.00273	0.0218	CbGeAlD
Alitretinoin—CRABP2—female gonad—ovarian cancer	0.00268	0.0214	CbGeAlD
Alitretinoin—RXRA—female gonad—ovarian cancer	0.00267	0.0213	CbGeAlD
Alitretinoin—CRABP2—vagina—ovarian cancer	0.00267	0.0213	CbGeAlD
Alitretinoin—RARB—female reproductive system—ovarian cancer	0.00264	0.021	CbGeAlD
Alitretinoin—CRABP1—testis—ovarian cancer	0.00263	0.021	CbGeAlD
Alitretinoin—RARA—decidua—ovarian cancer	0.00257	0.0205	CbGeAlD
Alitretinoin—RARA—endometrium—ovarian cancer	0.00244	0.0195	CbGeAlD
Alitretinoin—RARB—female gonad—ovarian cancer	0.0024	0.0191	CbGeAlD
Alitretinoin—RARG—uterus—ovarian cancer	0.00239	0.0191	CbGeAlD
Alitretinoin—RARB—vagina—ovarian cancer	0.00238	0.019	CbGeAlD
Alitretinoin—CRABP2—testis—ovarian cancer	0.00238	0.019	CbGeAlD
Alitretinoin—RARA—gonad—ovarian cancer	0.00226	0.0181	CbGeAlD
Alitretinoin—RARA—uterus—ovarian cancer	0.00225	0.018	CbGeAlD
Alitretinoin—RXRB—female gonad—ovarian cancer	0.0022	0.0176	CbGeAlD
Alitretinoin—RXRB—vagina—ovarian cancer	0.00219	0.0175	CbGeAlD
Alitretinoin—RARG—female reproductive system—ovarian cancer	0.00215	0.0172	CbGeAlD
Alitretinoin—RXRG—testis—ovarian cancer	0.00208	0.0166	CbGeAlD
Alitretinoin—RARA—female reproductive system—ovarian cancer	0.00202	0.0161	CbGeAlD
Alitretinoin—RARG—female gonad—ovarian cancer	0.00196	0.0156	CbGeAlD
Alitretinoin—RXRB—testis—ovarian cancer	0.00196	0.0156	CbGeAlD
Alitretinoin—RARG—vagina—ovarian cancer	0.00194	0.0155	CbGeAlD
Alitretinoin—RARA—bone marrow—ovarian cancer	0.00191	0.0152	CbGeAlD
Alitretinoin—RARA—female gonad—ovarian cancer	0.00184	0.0147	CbGeAlD
Alitretinoin—RARG—testis—ovarian cancer	0.00174	0.0139	CbGeAlD
Alitretinoin—RARA—testis—ovarian cancer	0.00163	0.013	CbGeAlD
Alitretinoin—RARB—lymph node—ovarian cancer	0.00154	0.0123	CbGeAlD
Alitretinoin—RARG—lymph node—ovarian cancer	0.00126	0.01	CbGeAlD
Alitretinoin—RARA—lymph node—ovarian cancer	0.00118	0.00944	CbGeAlD
Alitretinoin—ABCB1—myometrium—ovarian cancer	0.000659	0.00526	CbGeAlD
Alitretinoin—ABCB1—embryo—ovarian cancer	0.000634	0.00506	CbGeAlD
Alitretinoin—ABCB1—epithelium—ovarian cancer	0.000517	0.00413	CbGeAlD
Alitretinoin—ABCB1—uterine cervix—ovarian cancer	0.000513	0.00409	CbGeAlD
Alitretinoin—ABCB1—decidua—ovarian cancer	0.000488	0.0039	CbGeAlD
Alitretinoin—ABCB1—endometrium—ovarian cancer	0.000464	0.0037	CbGeAlD
Alitretinoin—ABCB1—gonad—ovarian cancer	0.00043	0.00343	CbGeAlD
Alitretinoin—ABCB1—uterus—ovarian cancer	0.000427	0.00341	CbGeAlD
Alitretinoin—ABCB1—female reproductive system—ovarian cancer	0.000384	0.00307	CbGeAlD
Alitretinoin—ABCB1—bone marrow—ovarian cancer	0.000363	0.00289	CbGeAlD
Alitretinoin—ABCB1—female gonad—ovarian cancer	0.000349	0.00279	CbGeAlD
Alitretinoin—ABCB1—vagina—ovarian cancer	0.000347	0.00277	CbGeAlD
Alitretinoin—ABCB1—testis—ovarian cancer	0.00031	0.00247	CbGeAlD
Alitretinoin—ABCB1—lymph node—ovarian cancer	0.000225	0.00179	CbGeAlD
Alitretinoin—Dyspepsia—Paclitaxel—ovarian cancer	0.000111	0.000349	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000111	0.000348	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000111	0.000348	CcSEcCtD
Alitretinoin—Stomatitis—Epirubicin—ovarian cancer	0.00011	0.000346	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—CYP1B1—ovarian cancer	0.00011	0.000677	CbGpPWpGaD
Alitretinoin—Conjunctivitis—Epirubicin—ovarian cancer	0.00011	0.000345	CcSEcCtD
Alitretinoin—Urinary tract infection—Epirubicin—ovarian cancer	0.00011	0.000345	CcSEcCtD
Alitretinoin—Dysuria—Doxorubicin—ovarian cancer	0.00011	0.000345	CcSEcCtD
Alitretinoin—Neutropenia—Doxorubicin—ovarian cancer	0.00011	0.000345	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	0.00011	0.000675	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	0.00011	0.000675	CbGpPWpGaD
Alitretinoin—Decreased appetite—Paclitaxel—ovarian cancer	0.00011	0.000344	CcSEcCtD
Alitretinoin—Dry mouth—Docetaxel—ovarian cancer	0.000109	0.000342	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000109	0.000342	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000109	0.000342	CcSEcCtD
Alitretinoin—Fatigue—Paclitaxel—ovarian cancer	0.000109	0.000341	CcSEcCtD
Alitretinoin—Sweating—Epirubicin—ovarian cancer	0.000109	0.00034	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—ovarian cancer	0.000109	0.00034	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000108	0.000665	CbGpPWpGaD
Alitretinoin—Pain—Paclitaxel—ovarian cancer	0.000108	0.000339	CcSEcCtD
Alitretinoin—Constipation—Paclitaxel—ovarian cancer	0.000108	0.000339	CcSEcCtD
Alitretinoin—Haematuria—Epirubicin—ovarian cancer	0.000108	0.000339	CcSEcCtD
Alitretinoin—Confusional state—Docetaxel—ovarian cancer	0.000108	0.000338	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000107	0.000336	CcSEcCtD
Alitretinoin—RARA—Generic Transcription Pathway—ESR1—ovarian cancer	0.000107	0.000659	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—ESR1—ovarian cancer	0.000107	0.000659	CbGpPWpGaD
Alitretinoin—Oedema—Docetaxel—ovarian cancer	0.000107	0.000336	CcSEcCtD
Alitretinoin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000107	0.000336	CcSEcCtD
Alitretinoin—Weight increased—Doxorubicin—ovarian cancer	0.000107	0.000335	CcSEcCtD
Alitretinoin—Epistaxis—Epirubicin—ovarian cancer	0.000107	0.000335	CcSEcCtD
Alitretinoin—Infection—Docetaxel—ovarian cancer	0.000106	0.000334	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000106	0.000654	CbGpPWpGaD
Alitretinoin—Weight decreased—Doxorubicin—ovarian cancer	0.000106	0.000333	CcSEcCtD
Alitretinoin—Sinusitis—Epirubicin—ovarian cancer	0.000106	0.000333	CcSEcCtD
Alitretinoin—Agranulocytosis—Epirubicin—ovarian cancer	0.000106	0.000331	CcSEcCtD
Alitretinoin—Pneumonia—Doxorubicin—ovarian cancer	0.000105	0.00033	CcSEcCtD
Alitretinoin—Shock—Docetaxel—ovarian cancer	0.000105	0.00033	CcSEcCtD
Alitretinoin—Nervous system disorder—Docetaxel—ovarian cancer	0.000105	0.000329	CcSEcCtD
Alitretinoin—Thrombocytopenia—Docetaxel—ovarian cancer	0.000105	0.000329	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—ovarian cancer	0.000105	0.000328	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—ovarian cancer	0.000105	0.000328	CcSEcCtD
Alitretinoin—Infestation—Doxorubicin—ovarian cancer	0.000105	0.000328	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—PGR—ovarian cancer	0.000105	0.000644	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—PARP1—ovarian cancer	0.000105	0.000643	CbGpPWpGaD
Alitretinoin—Tachycardia—Docetaxel—ovarian cancer	0.000105	0.000328	CcSEcCtD
Alitretinoin—Feeling abnormal—Paclitaxel—ovarian cancer	0.000104	0.000326	CcSEcCtD
Alitretinoin—Skin disorder—Docetaxel—ovarian cancer	0.000104	0.000326	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000104	0.000326	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	0.000104	0.000638	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000103	0.000324	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—ovarian cancer	0.000103	0.000323	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—PGR—ovarian cancer	0.000103	0.000632	CbGpPWpGaD
Alitretinoin—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000103	0.000322	CcSEcCtD
Alitretinoin—Haemoglobin—Epirubicin—ovarian cancer	0.000102	0.00032	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—ovarian cancer	0.000102	0.00032	CcSEcCtD
Alitretinoin—Anorexia—Docetaxel—ovarian cancer	0.000102	0.00032	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—ovarian cancer	0.000102	0.000319	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—ovarian cancer	0.000102	0.000319	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—ovarian cancer	0.000102	0.000319	CcSEcCtD
Alitretinoin—Haemorrhage—Epirubicin—ovarian cancer	0.000102	0.000319	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—NR5A1—ovarian cancer	0.000101	0.000622	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Epirubicin—ovarian cancer	0.000101	0.000317	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—ovarian cancer	0.000101	0.000316	CcSEcCtD
Alitretinoin—RARB—Gene Expression—PGR—ovarian cancer	0.000101	0.00062	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000101	0.00062	CbGpPWpGaD
Alitretinoin—Sweating—Doxorubicin—ovarian cancer	0.0001	0.000315	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—ovarian cancer	0.0001	0.000315	CcSEcCtD
Alitretinoin—Urticaria—Paclitaxel—ovarian cancer	0.0001	0.000315	CcSEcCtD
Alitretinoin—Oedema peripheral—Epirubicin—ovarian cancer	0.0001	0.000314	CcSEcCtD
Alitretinoin—Hypotension—Docetaxel—ovarian cancer	0.0001	0.000314	CcSEcCtD
Alitretinoin—Haematuria—Doxorubicin—ovarian cancer	9.99e-05	0.000313	CcSEcCtD
Alitretinoin—Abdominal pain—Paclitaxel—ovarian cancer	9.99e-05	0.000313	CcSEcCtD
Alitretinoin—Body temperature increased—Paclitaxel—ovarian cancer	9.99e-05	0.000313	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—ovarian cancer	9.97e-05	0.000312	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	9.94e-05	0.000611	CbGpPWpGaD
Alitretinoin—Epistaxis—Doxorubicin—ovarian cancer	9.88e-05	0.00031	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—ovarian cancer	9.83e-05	0.000308	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—CTNNB1—ovarian cancer	9.83e-05	0.000604	CbGpPWpGaD
Alitretinoin—Visual impairment—Epirubicin—ovarian cancer	9.8e-05	0.000307	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—ovarian cancer	9.78e-05	0.000307	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—PPP2R1A—ovarian cancer	9.76e-05	0.0006	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PPP2R1A—ovarian cancer	9.76e-05	0.0006	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.76e-05	0.000306	CcSEcCtD
Alitretinoin—RXRA—Generic Transcription Pathway—PARP1—ovarian cancer	9.73e-05	0.000598	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.71e-05	0.000597	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.71e-05	0.000597	CbGpPWpGaD
Alitretinoin—Insomnia—Docetaxel—ovarian cancer	9.68e-05	0.000304	CcSEcCtD
Alitretinoin—RXRB—Gene Expression—PGR—ovarian cancer	9.67e-05	0.000595	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—PGR—ovarian cancer	9.67e-05	0.000595	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	9.62e-05	0.000591	CbGpPWpGaD
Alitretinoin—Paraesthesia—Docetaxel—ovarian cancer	9.62e-05	0.000301	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—ovarian cancer	9.61e-05	0.000301	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—PARP1—ovarian cancer	9.56e-05	0.000588	CbGpPWpGaD
Alitretinoin—Dyspnoea—Docetaxel—ovarian cancer	9.55e-05	0.000299	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	9.53e-05	0.000586	CbGpPWpGaD
Alitretinoin—Somnolence—Docetaxel—ovarian cancer	9.52e-05	0.000298	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—ovarian cancer	9.5e-05	0.000298	CcSEcCtD
Alitretinoin—Tinnitus—Epirubicin—ovarian cancer	9.48e-05	0.000297	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—ovarian cancer	9.45e-05	0.000296	CcSEcCtD
Alitretinoin—Flushing—Epirubicin—ovarian cancer	9.43e-05	0.000296	CcSEcCtD
Alitretinoin—Dyspepsia—Docetaxel—ovarian cancer	9.43e-05	0.000296	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—ovarian cancer	9.41e-05	0.000295	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—ovarian cancer	9.41e-05	0.000295	CcSEcCtD
Alitretinoin—RARB—Gene Expression—PARP1—ovarian cancer	9.38e-05	0.000577	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Doxorubicin—ovarian cancer	9.36e-05	0.000293	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—ovarian cancer	9.34e-05	0.000293	CcSEcCtD
Alitretinoin—Decreased appetite—Docetaxel—ovarian cancer	9.31e-05	0.000292	CcSEcCtD
Alitretinoin—Hypersensitivity—Paclitaxel—ovarian cancer	9.31e-05	0.000292	CcSEcCtD
Alitretinoin—Urinary tract disorder—Doxorubicin—ovarian cancer	9.29e-05	0.000291	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—ovarian cancer	9.27e-05	0.000291	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Docetaxel—ovarian cancer	9.24e-05	0.00029	CcSEcCtD
Alitretinoin—Fatigue—Docetaxel—ovarian cancer	9.23e-05	0.000289	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—ovarian cancer	9.22e-05	0.000289	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	9.22e-05	0.000567	CbGpPWpGaD
Alitretinoin—Urethral disorder—Doxorubicin—ovarian cancer	9.22e-05	0.000289	CcSEcCtD
Alitretinoin—Pain—Docetaxel—ovarian cancer	9.16e-05	0.000287	CcSEcCtD
Alitretinoin—Constipation—Docetaxel—ovarian cancer	9.16e-05	0.000287	CcSEcCtD
Alitretinoin—Chills—Epirubicin—ovarian cancer	9.12e-05	0.000286	CcSEcCtD
Alitretinoin—Arrhythmia—Epirubicin—ovarian cancer	9.08e-05	0.000285	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	9.08e-05	0.000558	CbGpPWpGaD
Alitretinoin—Visual impairment—Doxorubicin—ovarian cancer	9.06e-05	0.000284	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—ABCB1—ovarian cancer	9.06e-05	0.000557	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ABCB1—ovarian cancer	9.06e-05	0.000557	CbGpPWpGaD
Alitretinoin—Asthenia—Paclitaxel—ovarian cancer	9.06e-05	0.000284	CcSEcCtD
Alitretinoin—RXRB—Gene Expression—PARP1—ovarian cancer	8.99e-05	0.000553	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—PARP1—ovarian cancer	8.99e-05	0.000553	CbGpPWpGaD
Alitretinoin—Alopecia—Epirubicin—ovarian cancer	8.98e-05	0.000282	CcSEcCtD
Alitretinoin—Pruritus—Paclitaxel—ovarian cancer	8.94e-05	0.00028	CcSEcCtD
Alitretinoin—Mental disorder—Epirubicin—ovarian cancer	8.91e-05	0.000279	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—TYMS—ovarian cancer	8.9e-05	0.000547	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—TYMS—ovarian cancer	8.9e-05	0.000547	CbGpPWpGaD
Alitretinoin—Erythema multiforme—Doxorubicin—ovarian cancer	8.89e-05	0.000279	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—ovarian cancer	8.85e-05	0.000277	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—ovarian cancer	8.85e-05	0.000277	CcSEcCtD
Alitretinoin—Feeling abnormal—Docetaxel—ovarian cancer	8.82e-05	0.000277	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—ovarian cancer	8.79e-05	0.000276	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—ovarian cancer	8.77e-05	0.000275	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Docetaxel—ovarian cancer	8.76e-05	0.000275	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—ovarian cancer	8.73e-05	0.000274	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—ovarian cancer	8.72e-05	0.000273	CcSEcCtD
Alitretinoin—Tension—Epirubicin—ovarian cancer	8.68e-05	0.000272	CcSEcCtD
Alitretinoin—Diarrhoea—Paclitaxel—ovarian cancer	8.64e-05	0.000271	CcSEcCtD
Alitretinoin—Nervousness—Epirubicin—ovarian cancer	8.6e-05	0.000269	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—STAT3—ovarian cancer	8.57e-05	0.000527	CbGpPWpGaD
Alitretinoin—Back pain—Epirubicin—ovarian cancer	8.56e-05	0.000268	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—ovarian cancer	8.53e-05	0.000268	CcSEcCtD
Alitretinoin—RARG—Gene Expression—PPP2R1A—ovarian cancer	8.48e-05	0.000521	CbGpPWpGaD
Alitretinoin—Abdominal pain—Docetaxel—ovarian cancer	8.46e-05	0.000265	CcSEcCtD
Alitretinoin—Body temperature increased—Docetaxel—ovarian cancer	8.46e-05	0.000265	CcSEcCtD
Alitretinoin—Chills—Doxorubicin—ovarian cancer	8.44e-05	0.000265	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—ovarian cancer	8.4e-05	0.000263	CcSEcCtD
Alitretinoin—Dizziness—Paclitaxel—ovarian cancer	8.35e-05	0.000262	CcSEcCtD
Alitretinoin—Vision blurred—Epirubicin—ovarian cancer	8.34e-05	0.000261	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—ovarian cancer	8.31e-05	0.000261	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	8.26e-05	0.000508	CbGpPWpGaD
Alitretinoin—Mental disorder—Doxorubicin—ovarian cancer	8.24e-05	0.000258	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.22e-05	0.000505	CbGpPWpGaD
Alitretinoin—Ill-defined disorder—Epirubicin—ovarian cancer	8.21e-05	0.000257	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—ovarian cancer	8.19e-05	0.000257	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—ovarian cancer	8.19e-05	0.000257	CcSEcCtD
Alitretinoin—Anaemia—Epirubicin—ovarian cancer	8.18e-05	0.000256	CcSEcCtD
Alitretinoin—Agitation—Epirubicin—ovarian cancer	8.13e-05	0.000255	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	8.12e-05	0.000499	CbGpPWpGaD
Alitretinoin—Flatulence—Doxorubicin—ovarian cancer	8.07e-05	0.000253	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—ovarian cancer	8.04e-05	0.000252	CcSEcCtD
Alitretinoin—Vomiting—Paclitaxel—ovarian cancer	8.03e-05	0.000252	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—ovarian cancer	7.98e-05	0.00025	CcSEcCtD
Alitretinoin—Rash—Paclitaxel—ovarian cancer	7.97e-05	0.00025	CcSEcCtD
Alitretinoin—Dermatitis—Paclitaxel—ovarian cancer	7.96e-05	0.000249	CcSEcCtD
Alitretinoin—Nervousness—Doxorubicin—ovarian cancer	7.95e-05	0.000249	CcSEcCtD
Alitretinoin—Syncope—Epirubicin—ovarian cancer	7.94e-05	0.000249	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—ovarian cancer	7.92e-05	0.000248	CcSEcCtD
Alitretinoin—Headache—Paclitaxel—ovarian cancer	7.91e-05	0.000248	CcSEcCtD
Alitretinoin—Hypersensitivity—Docetaxel—ovarian cancer	7.89e-05	0.000247	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	7.86e-05	0.000483	CbGpPWpGaD
Alitretinoin—Palpitations—Epirubicin—ovarian cancer	7.82e-05	0.000245	CcSEcCtD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	7.79e-05	0.000479	CbGpPWpGaD
Alitretinoin—Loss of consciousness—Epirubicin—ovarian cancer	7.78e-05	0.000244	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—PPP2R1A—ovarian cancer	7.76e-05	0.000477	CbGpPWpGaD
Alitretinoin—Cough—Epirubicin—ovarian cancer	7.72e-05	0.000242	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—ovarian cancer	7.72e-05	0.000242	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	7.68e-05	0.000472	CbGpPWpGaD
Alitretinoin—Asthenia—Docetaxel—ovarian cancer	7.68e-05	0.000241	CcSEcCtD
Alitretinoin—Convulsion—Epirubicin—ovarian cancer	7.67e-05	0.00024	CcSEcCtD
Alitretinoin—RXRA—Metabolism—CYTB—ovarian cancer	7.66e-05	0.000471	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	7.65e-05	0.00047	CbGpPWpGaD
Alitretinoin—Hypertension—Epirubicin—ovarian cancer	7.64e-05	0.00024	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	7.62e-05	0.000469	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	7.62e-05	0.000469	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—PPP2R1A—ovarian cancer	7.61e-05	0.000468	CbGpPWpGaD
Alitretinoin—Ill-defined disorder—Doxorubicin—ovarian cancer	7.6e-05	0.000238	CcSEcCtD
Alitretinoin—Pruritus—Docetaxel—ovarian cancer	7.58e-05	0.000238	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—ovarian cancer	7.57e-05	0.000237	CcSEcCtD
Alitretinoin—Chest pain—Epirubicin—ovarian cancer	7.53e-05	0.000236	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—ovarian cancer	7.53e-05	0.000236	CcSEcCtD
Alitretinoin—Arthralgia—Epirubicin—ovarian cancer	7.53e-05	0.000236	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—ovarian cancer	7.52e-05	0.000236	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—ovarian cancer	7.51e-05	0.000235	CcSEcCtD
Alitretinoin—Nausea—Paclitaxel—ovarian cancer	7.5e-05	0.000235	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	7.5e-05	0.000461	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.48e-05	0.000235	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.48e-05	0.00046	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	7.46e-05	0.000459	CbGpPWpGaD
Alitretinoin—Discomfort—Epirubicin—ovarian cancer	7.44e-05	0.000233	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	7.42e-05	0.000456	CbGpPWpGaD
Alitretinoin—Malaise—Doxorubicin—ovarian cancer	7.38e-05	0.000231	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—ovarian cancer	7.37e-05	0.000231	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—ovarian cancer	7.34e-05	0.00023	CcSEcCtD
Alitretinoin—Diarrhoea—Docetaxel—ovarian cancer	7.33e-05	0.00023	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	7.3e-05	0.000449	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—PPP2R1A—ovarian cancer	7.29e-05	0.000448	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—PPP2R1A—ovarian cancer	7.29e-05	0.000448	CbGpPWpGaD
Alitretinoin—Confusional state—Epirubicin—ovarian cancer	7.28e-05	0.000228	CcSEcCtD
Alitretinoin—Palpitations—Doxorubicin—ovarian cancer	7.24e-05	0.000227	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	7.23e-05	0.000444	CbGpPWpGaD
Alitretinoin—Anaphylactic shock—Epirubicin—ovarian cancer	7.22e-05	0.000226	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—ovarian cancer	7.22e-05	0.000226	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—ovarian cancer	7.2e-05	0.000226	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	7.18e-05	0.000442	CbGpPWpGaD
Alitretinoin—Infection—Epirubicin—ovarian cancer	7.18e-05	0.000225	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—CAV1—ovarian cancer	7.17e-05	0.000441	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CAV1—ovarian cancer	7.17e-05	0.000441	CbGpPWpGaD
Alitretinoin—Cough—Doxorubicin—ovarian cancer	7.15e-05	0.000224	CcSEcCtD
Alitretinoin—Shock—Epirubicin—ovarian cancer	7.11e-05	0.000223	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—ovarian cancer	7.09e-05	0.000222	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—ovarian cancer	7.08e-05	0.000222	CcSEcCtD
Alitretinoin—Dizziness—Docetaxel—ovarian cancer	7.08e-05	0.000222	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—ovarian cancer	7.07e-05	0.000222	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—ovarian cancer	7.07e-05	0.000222	CcSEcCtD
Alitretinoin—Tachycardia—Epirubicin—ovarian cancer	7.05e-05	0.000221	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	7.04e-05	0.000433	CbGpPWpGaD
Alitretinoin—Skin disorder—Epirubicin—ovarian cancer	7.02e-05	0.00022	CcSEcCtD
Alitretinoin—Hyperhidrosis—Epirubicin—ovarian cancer	6.98e-05	0.000219	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—ovarian cancer	6.97e-05	0.000219	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—ovarian cancer	6.97e-05	0.000219	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—ovarian cancer	6.97e-05	0.000219	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—ovarian cancer	6.95e-05	0.000218	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	6.95e-05	0.000427	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.92e-05	0.000217	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—ovarian cancer	6.89e-05	0.000216	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—ovarian cancer	6.88e-05	0.000216	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.85e-05	0.000421	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.85e-05	0.000421	CbGpPWpGaD
Alitretinoin—Dry mouth—Doxorubicin—ovarian cancer	6.82e-05	0.000214	CcSEcCtD
Alitretinoin—Vomiting—Docetaxel—ovarian cancer	6.81e-05	0.000213	CcSEcCtD
Alitretinoin—Rash—Docetaxel—ovarian cancer	6.75e-05	0.000212	CcSEcCtD
Alitretinoin—Hypotension—Epirubicin—ovarian cancer	6.75e-05	0.000212	CcSEcCtD
Alitretinoin—Dermatitis—Docetaxel—ovarian cancer	6.75e-05	0.000211	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—ovarian cancer	6.74e-05	0.000211	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	6.73e-05	0.000414	CbGpPWpGaD
Alitretinoin—Headache—Docetaxel—ovarian cancer	6.71e-05	0.00021	CcSEcCtD
Alitretinoin—RXRA—Metabolism—BRIP1—ovarian cancer	6.69e-05	0.000411	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PPP1CC—ovarian cancer	6.69e-05	0.000411	CbGpPWpGaD
Alitretinoin—Oedema—Doxorubicin—ovarian cancer	6.68e-05	0.00021	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—ovarian cancer	6.68e-05	0.00021	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—ovarian cancer	6.64e-05	0.000208	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.58e-05	0.000206	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—ovarian cancer	6.57e-05	0.000206	CcSEcCtD
Alitretinoin—Nervous system disorder—Doxorubicin—ovarian cancer	6.55e-05	0.000205	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—ovarian cancer	6.54e-05	0.000205	CcSEcCtD
Alitretinoin—CRABP2—Metabolism—PIK3CG—ovarian cancer	6.53e-05	0.000402	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PIK3CG—ovarian cancer	6.53e-05	0.000402	CbGpPWpGaD
Alitretinoin—Insomnia—Epirubicin—ovarian cancer	6.53e-05	0.000205	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—ovarian cancer	6.52e-05	0.000204	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—ovarian cancer	6.49e-05	0.000204	CcSEcCtD
Alitretinoin—RARG—Generic Transcription Pathway—MYC—ovarian cancer	6.49e-05	0.000399	CbGpPWpGaD
Alitretinoin—Paraesthesia—Epirubicin—ovarian cancer	6.49e-05	0.000203	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—ovarian cancer	6.46e-05	0.000203	CcSEcCtD
Alitretinoin—Dyspnoea—Epirubicin—ovarian cancer	6.44e-05	0.000202	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—ovarian cancer	6.42e-05	0.000201	CcSEcCtD
Alitretinoin—Anorexia—Doxorubicin—ovarian cancer	6.37e-05	0.0002	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	6.36e-05	0.000391	CbGpPWpGaD
Alitretinoin—Nausea—Docetaxel—ovarian cancer	6.36e-05	0.000199	CcSEcCtD
Alitretinoin—Dyspepsia—Epirubicin—ovarian cancer	6.36e-05	0.000199	CcSEcCtD
Alitretinoin—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	6.34e-05	0.00039	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	6.34e-05	0.00039	CbGpPWpGaD
Alitretinoin—Decreased appetite—Epirubicin—ovarian cancer	6.28e-05	0.000197	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	6.26e-05	0.000385	CbGpPWpGaD
Alitretinoin—Hypotension—Doxorubicin—ovarian cancer	6.24e-05	0.000196	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.24e-05	0.000195	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—ovarian cancer	6.23e-05	0.000195	CcSEcCtD
Alitretinoin—CYP1A2—Biological oxidations—CYP1B1—ovarian cancer	6.22e-05	0.000382	CbGpPWpGaD
Alitretinoin—Constipation—Epirubicin—ovarian cancer	6.18e-05	0.000194	CcSEcCtD
Alitretinoin—Pain—Epirubicin—ovarian cancer	6.18e-05	0.000194	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP1B1—ovarian cancer	6.13e-05	0.000377	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	6.09e-05	0.000374	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.09e-05	0.000191	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	6.07e-05	0.000373	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CASP3—ovarian cancer	6.07e-05	0.000373	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL2—ovarian cancer	6.06e-05	0.000373	CbGpPWpGaD
Alitretinoin—Insomnia—Doxorubicin—ovarian cancer	6.04e-05	0.000189	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	6.02e-05	0.00037	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—ESR1—ovarian cancer	6e-05	0.000369	CbGpPWpGaD
Alitretinoin—Paraesthesia—Doxorubicin—ovarian cancer	6e-05	0.000188	CcSEcCtD
Alitretinoin—RXRA—Adipogenesis—IL6—ovarian cancer	5.99e-05	0.000368	CbGpPWpGaD
Alitretinoin—Dyspnoea—Doxorubicin—ovarian cancer	5.96e-05	0.000187	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—ovarian cancer	5.95e-05	0.000187	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	5.95e-05	0.000366	CbGpPWpGaD
Alitretinoin—Somnolence—Doxorubicin—ovarian cancer	5.94e-05	0.000186	CcSEcCtD
Alitretinoin—RXRG—Generic Transcription Pathway—MYC—ovarian cancer	5.93e-05	0.000365	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Epirubicin—ovarian cancer	5.91e-05	0.000185	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	5.9e-05	0.000363	CbGpPWpGaD
Alitretinoin—Dyspepsia—Doxorubicin—ovarian cancer	5.88e-05	0.000184	CcSEcCtD
Alitretinoin—RXRA—Transmembrane transport of small molecules—ABCB1—ovarian cancer	5.86e-05	0.00036	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	5.85e-05	0.00036	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	5.83e-05	0.000359	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.82e-05	0.000358	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—MYC—ovarian cancer	5.82e-05	0.000358	CbGpPWpGaD
Alitretinoin—Decreased appetite—Doxorubicin—ovarian cancer	5.81e-05	0.000182	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	5.79e-05	0.000356	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—YAP1—ovarian cancer	5.77e-05	0.000355	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.77e-05	0.000181	CcSEcCtD
Alitretinoin—Fatigue—Doxorubicin—ovarian cancer	5.76e-05	0.000181	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—PIK3CD—ovarian cancer	5.74e-05	0.000353	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PIK3CD—ovarian cancer	5.74e-05	0.000353	CbGpPWpGaD
Alitretinoin—Urticaria—Epirubicin—ovarian cancer	5.74e-05	0.00018	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	5.73e-05	0.000352	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	5.72e-05	0.000352	CbGpPWpGaD
Alitretinoin—Pain—Doxorubicin—ovarian cancer	5.71e-05	0.000179	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—ovarian cancer	5.71e-05	0.000179	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—ovarian cancer	5.71e-05	0.000179	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—ovarian cancer	5.71e-05	0.000179	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	5.71e-05	0.000351	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	5.7e-05	0.000351	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	5.7e-05	0.000351	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—ESR1—ovarian cancer	5.59e-05	0.000344	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—MYC—ovarian cancer	5.58e-05	0.000343	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—MYC—ovarian cancer	5.58e-05	0.000343	CbGpPWpGaD
Alitretinoin—Feeling abnormal—Doxorubicin—ovarian cancer	5.51e-05	0.000173	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—ESR1—ovarian cancer	5.49e-05	0.000338	CbGpPWpGaD
Alitretinoin—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.46e-05	0.000171	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	5.41e-05	0.000332	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	5.39e-05	0.000331	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—ESR1—ovarian cancer	5.39e-05	0.000331	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Epirubicin—ovarian cancer	5.32e-05	0.000167	CcSEcCtD
Alitretinoin—Urticaria—Doxorubicin—ovarian cancer	5.31e-05	0.000166	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MET—ovarian cancer	5.28e-05	0.000325	CbGpPWpGaD
Alitretinoin—Body temperature increased—Doxorubicin—ovarian cancer	5.28e-05	0.000166	CcSEcCtD
Alitretinoin—Abdominal pain—Doxorubicin—ovarian cancer	5.28e-05	0.000166	CcSEcCtD
Alitretinoin—Asthenia—Epirubicin—ovarian cancer	5.18e-05	0.000162	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—IL6ST—ovarian cancer	5.18e-05	0.000318	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—ESR1—ovarian cancer	5.16e-05	0.000317	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—ESR1—ovarian cancer	5.16e-05	0.000317	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	5.15e-05	0.000317	CbGpPWpGaD
Alitretinoin—Pruritus—Epirubicin—ovarian cancer	5.11e-05	0.00016	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—PGR—ovarian cancer	5.04e-05	0.00031	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PIK3CB—ovarian cancer	5.01e-05	0.000308	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PIK3CB—ovarian cancer	5.01e-05	0.000308	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.97e-05	0.000305	CbGpPWpGaD
Alitretinoin—Diarrhoea—Epirubicin—ovarian cancer	4.94e-05	0.000155	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—ovarian cancer	4.92e-05	0.000154	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.88e-05	0.0003	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.81e-05	0.000295	CbGpPWpGaD
Alitretinoin—Asthenia—Doxorubicin—ovarian cancer	4.79e-05	0.00015	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.79e-05	0.000295	CbGpPWpGaD
Alitretinoin—Dizziness—Epirubicin—ovarian cancer	4.78e-05	0.00015	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—NME2—ovarian cancer	4.75e-05	0.000292	CbGpPWpGaD
Alitretinoin—Pruritus—Doxorubicin—ovarian cancer	4.73e-05	0.000148	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—PARP1—ovarian cancer	4.69e-05	0.000288	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.6e-05	0.000283	CbGpPWpGaD
Alitretinoin—Vomiting—Epirubicin—ovarian cancer	4.59e-05	0.000144	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	4.58e-05	0.000282	CbGpPWpGaD
Alitretinoin—Diarrhoea—Doxorubicin—ovarian cancer	4.57e-05	0.000143	CcSEcCtD
Alitretinoin—Rash—Epirubicin—ovarian cancer	4.55e-05	0.000143	CcSEcCtD
Alitretinoin—Dermatitis—Epirubicin—ovarian cancer	4.55e-05	0.000143	CcSEcCtD
Alitretinoin—Headache—Epirubicin—ovarian cancer	4.52e-05	0.000142	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	4.5e-05	0.000276	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—YAP1—ovarian cancer	4.49e-05	0.000276	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.44e-05	0.000273	CbGpPWpGaD
Alitretinoin—Dizziness—Doxorubicin—ovarian cancer	4.42e-05	0.000139	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MMP2—ovarian cancer	4.41e-05	0.000271	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PTEN—ovarian cancer	4.33e-05	0.000266	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTEN—ovarian cancer	4.33e-05	0.000266	CbGpPWpGaD
Alitretinoin—Nausea—Epirubicin—ovarian cancer	4.29e-05	0.000134	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.25e-05	0.000261	CbGpPWpGaD
Alitretinoin—Vomiting—Doxorubicin—ovarian cancer	4.25e-05	0.000133	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—ovarian cancer	4.21e-05	0.000132	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—ovarian cancer	4.21e-05	0.000132	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—ovarian cancer	4.19e-05	0.000131	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	4.06e-05	0.00025	CbGpPWpGaD
Alitretinoin—Nausea—Doxorubicin—ovarian cancer	3.97e-05	0.000124	CcSEcCtD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.9e-05	0.00024	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—ERBB2—ovarian cancer	3.86e-05	0.000237	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—PPP2R1A—ovarian cancer	3.8e-05	0.000234	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	3.8e-05	0.000233	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NME2—ovarian cancer	3.79e-05	0.000233	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—FASN—ovarian cancer	3.66e-05	0.000225	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—SLC5A5—ovarian cancer	3.6e-05	0.000221	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—SLC2A1—ovarian cancer	3.48e-05	0.000214	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.4e-05	0.000209	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CTNNB1—ovarian cancer	3.38e-05	0.000208	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP1B1—ovarian cancer	3.33e-05	0.000205	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP9—ovarian cancer	3.31e-05	0.000204	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.3e-05	0.000203	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.22e-05	0.000198	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—MAPK3—ovarian cancer	3.21e-05	0.000197	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—MYC—ovarian cancer	3.12e-05	0.000192	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.07e-05	0.000189	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYTB—ovarian cancer	3.06e-05	0.000188	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.06e-05	0.000188	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PIK3CA—ovarian cancer	3.05e-05	0.000188	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PIK3CA—ovarian cancer	3.05e-05	0.000188	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3e-05	0.000184	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—VEGFA—ovarian cancer	2.97e-05	0.000183	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.97e-05	0.000182	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PPP2R1A—ovarian cancer	2.96e-05	0.000182	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—STAT3—ovarian cancer	2.95e-05	0.000181	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.94e-05	0.000181	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—NRAS—ovarian cancer	2.94e-05	0.000181	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—MAPK3—ovarian cancer	2.94e-05	0.000181	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.92e-05	0.000179	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—MYC—ovarian cancer	2.91e-05	0.000179	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.89e-05	0.000178	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—MAPK3—ovarian cancer	2.88e-05	0.000177	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—MYC—ovarian cancer	2.86e-05	0.000176	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.81e-05	0.000173	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MAPK3—ovarian cancer	2.81e-05	0.000173	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—MYC—ovarian cancer	2.8e-05	0.000172	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—MAPK3—ovarian cancer	2.76e-05	0.00017	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—MAPK3—ovarian cancer	2.76e-05	0.00017	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ABCB1—ovarian cancer	2.74e-05	0.000169	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—TYMS—ovarian cancer	2.69e-05	0.000166	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ESR1—ovarian cancer	2.69e-05	0.000165	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—MYC—ovarian cancer	2.69e-05	0.000165	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—MYC—ovarian cancer	2.69e-05	0.000165	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MAPK1—ovarian cancer	2.68e-05	0.000165	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EGFR—ovarian cancer	2.68e-05	0.000165	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.67e-05	0.000164	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—BRIP1—ovarian cancer	2.67e-05	0.000164	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.62e-05	0.000161	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.54e-05	0.000156	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—KRAS—ovarian cancer	2.53e-05	0.000155	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—AKT1—ovarian cancer	2.49e-05	0.000153	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—AKT1—ovarian cancer	2.49e-05	0.000153	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYTB—ovarian cancer	2.44e-05	0.00015	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.4e-05	0.000148	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.39e-05	0.000147	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.34e-05	0.000144	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.29e-05	0.000141	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.29e-05	0.000141	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CAV1—ovarian cancer	2.17e-05	0.000134	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—AKT1—ovarian cancer	2.17e-05	0.000133	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.16e-05	0.000133	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—HRAS—ovarian cancer	2.15e-05	0.000132	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PPP1CC—ovarian cancer	2.13e-05	0.000131	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—BRIP1—ovarian cancer	2.13e-05	0.000131	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.07e-05	0.000128	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—IL6—ovarian cancer	2.06e-05	0.000126	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.99e-05	0.000122	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—AKT1—ovarian cancer	1.98e-05	0.000122	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CG—ovarian cancer	1.98e-05	0.000122	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—AKT1—ovarian cancer	1.94e-05	0.000119	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.92e-05	0.000118	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—AKT1—ovarian cancer	1.9e-05	0.000117	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—AKT1—ovarian cancer	1.86e-05	0.000115	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—AKT1—ovarian cancer	1.86e-05	0.000115	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—YAP1—ovarian cancer	1.79e-05	0.00011	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CD—ovarian cancer	1.74e-05	0.000107	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.62e-05	9.97e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.56e-05	9.56e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CB—ovarian cancer	1.52e-05	9.32e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—FASN—ovarian cancer	1.46e-05	8.99e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—MAPK3—ovarian cancer	1.44e-05	8.85e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.44e-05	8.84e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—YAP1—ovarian cancer	1.43e-05	8.8e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.42e-05	8.71e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—MYC—ovarian cancer	1.4e-05	8.61e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.39e-05	8.54e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.33e-05	8.19e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTEN—ovarian cancer	1.31e-05	8.05e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.25e-05	7.66e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.18e-05	7.26e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—FASN—ovarian cancer	1.17e-05	7.18e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC5A5—ovarian cancer	1.15e-05	7.06e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—SLC2A1—ovarian cancer	1.11e-05	6.82e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.09e-05	6.68e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—TYMS—ovarian cancer	1.08e-05	6.62e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP1B1—ovarian cancer	1.06e-05	6.54e-05	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—AKT1—ovarian cancer	9.71e-06	5.97e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	9.43e-06	5.8e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.38e-06	5.77e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PIK3CA—ovarian cancer	9.24e-06	5.68e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ABCB1—ovarian cancer	8.75e-06	5.38e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CAV1—ovarian cancer	8.68e-06	5.34e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—TYMS—ovarian cancer	8.6e-06	5.29e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CG—ovarian cancer	7.91e-06	4.86e-05	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—AKT1—ovarian cancer	7.55e-06	4.64e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CD—ovarian cancer	6.95e-06	4.27e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CAV1—ovarian cancer	6.93e-06	4.26e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.62e-06	4.07e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CG—ovarian cancer	6.31e-06	3.88e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CB—ovarian cancer	6.06e-06	3.72e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CD—ovarian cancer	5.55e-06	3.41e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTEN—ovarian cancer	5.23e-06	3.22e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CB—ovarian cancer	4.84e-06	2.97e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTEN—ovarian cancer	4.18e-06	2.57e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.69e-06	2.27e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—AKT1—ovarian cancer	3.02e-06	1.85e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PIK3CA—ovarian cancer	2.95e-06	1.81e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—AKT1—ovarian cancer	2.41e-06	1.48e-05	CbGpPWpGaD
